PT  - JOURNAL ARTICLE
AU  - Meizlish, Matthew L.
AU  - Pine, Alexander B.
AU  - Bishai, Jason D.
AU  - Goshua, George
AU  - Nadelmann, Emily R.
AU  - Simonov, Michael
AU  - Chang, C-Hong
AU  - Zhang, Hanming
AU  - Shallow, Marcus
AU  - Bahel, Parveen
AU  - Owusu, Kent
AU  - Yamamoto, Yu
AU  - Arora, Tanima
AU  - Atri, Deepak S.
AU  - Patel, Amisha
AU  - Gbyli, Rana
AU  - Kwan, Jennifer
AU  - Won, Christine H.
AU  - Cruz, Charles Dela
AU  - Price, Christina
AU  - Koff, Jonathan
AU  - King, Brett A.
AU  - Rinder, Henry M.
AU  - Wilson, F. Perry
AU  - Hwa, John
AU  - Halene, Stephanie
AU  - Damsky, William
AU  - Dijk, David van
AU  - Lee, Alfred I.
AU  - Chun, Hyung J.
TI  - A neutrophil activation signature predicts critical illness and mortality in COVID-19
AID  - 10.1101/2020.09.01.20183897
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.01.20183897
4099  - http://medrxiv.org/content/early/2020/09/02/2020.09.01.20183897.short
4100  - http://medrxiv.org/content/early/2020/09/02/2020.09.01.20183897.full
AB  - Pathologic immune hyperactivation is emerging as a key feature of critical illness in COVID-19, but the mechanisms involved remain poorly understood. We carried out proteomic profiling of plasma from cross-sectional and longitudinal cohorts of hospitalized patients with COVID-19 and analyzed clinical data from our health system database of over 3,300 patients. Using a machine learning algorithm, we identified a prominent signature of neutrophil activation, including resistin, lipocalin-2, HGF, IL-8, and G-CSF, as the strongest predictors of critical illness. Neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality. In the health system database, early elevations in developing and mature neutrophil counts also predicted higher mortality rates. Altogether, we define an essential role for neutrophil activation in the pathogenesis of severe COVID-19 and identify molecular neutrophil markers that distinguish patients at risk of future clinical decompensation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by a gift donation from Jack Levin to the Benign Hematology program at Yale, the National Institutes of Health (HL142818 to HJC, DK079310 and DK113191 to FPW, GM136651 and HL139116 to MLM), the American Heart Association (Transformational Project Award to HJC), and the DeLuca Center for Innovation in Hematology Research at Yale Cancer Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale University approved IRB #s:2000027792, 1401013259 and 2000028509All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A